A Risk-Benefit Assessment of Pharmacotherapy for Anxiety Disorders in Children and Adolescents

被引：0
|
作者：
Susan M. Hawkridge
Dan J. Stein
机构：
[1] University of Stellenbosch,Department of Psychiatry
来源：
Drug Safety | 1998年 / 19卷
关键词：
Adis International Limited; Fluoxetine; Anxiety Disorder; Imipramine; Social Phobia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Few pharmacotherapy trials have been undertaken in young people with anxiety disorders. Of those conducted, few are placebo-controlled or blinded, and often sample size is small, making interpretation of the data difficult.
引用
收藏
页码：283 / 297
页数：14
相关论文
共 50 条
  • [31] Assessment and Treatment of Anxiety Disorders in Children and Adolescents
    Anna M. Wehry
    Katja Beesdo-Baum
    Meghann M. Hennelly
    Sucheta D. Connolly
    Jeffrey R. Strawn
    Current Psychiatry Reports, 2015, 17
  • [32] A Risk-Benefit Assessment of Intra-Articular Corticosteroids in Rheumatic Disorders
    John A. Hunter
    Thomas H. Blyth
    Drug Safety, 1999, 21 : 353 - 365
  • [33] A risk-benefit assessment of intra-articular corticosteroids in rheumatic disorders
    Hunter, JA
    Blyth, TH
    DRUG SAFETY, 1999, 21 (05) : 353 - 365
  • [34] PHARMACOGENETICS OF ACUTE TREATMENT OF DEPRESSION AND ANXIETY IN CHILDREN AND ADOLESCENTS: IMPROVING THE RISK-BENEFIT RATIO FOR THE USE OF SSRIS IN THE PEDIATRIC POPULATION
    Kronenberg, Sefi
    Weizman, Abraham
    Frisch, Amos
    Michaelovsky, Elena
    Carmel, Miri
    Apter, Alan
    ISRAEL JOURNAL OF PSYCHIATRY AND RELATED SCIENCES, 2012, 49 (01): : 38 - 39
  • [35] Suicidal ideation in patients with chronic pain: The risk-benefit of pharmacotherapy
    Cheatle, Martin D.
    PAIN, 2014, 155 (12) : 2446 - 2447
  • [36] A Risk-Benefit Assessment of Antileukotrienes in Asthma
    Lewis J. Smith
    Drug Safety, 1998, 19 : 205 - 218
  • [37] A Risk-Benefit Assessment of Amifostine in Cytoprotection
    May Mabro
    Sandrine Faivre
    Eric Raymond
    Drug Safety, 1999, 21 : 367 - 387
  • [38] A RISK-BENEFIT ASSESSMENT OF RISPERIDONE IN SCHIZOPHRENIA
    CURTIS, VA
    KERWIN, RW
    DRUG SAFETY, 1995, 12 (02) : 139 - 145
  • [39] Risk-benefit ratio or risk-benefit nonsense?
    Ernst, E
    Resch, KL
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 1996, 49 (10) : 1203 - 1204
  • [40] THE RISK-BENEFIT ASSESSMENT OF ANTIDEPRESSANT DRUGS
    HENRY, JA
    MARTIN, AJ
    MEDICAL TOXICOLOGY AND ADVERSE DRUG EXPERIENCE, 1987, 2 (06): : 445 - 462
12345